Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20
Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.
Read original at benzingaStocks · News reference
Kanzhun Sees Q3 Sales $355.190M-$368.454M vs $361.520M Est
Kanzhun (NASDAQ:BZ) sees Q3 sales of $355.190 million-$368.454 million vs $361.520 million analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 11:24 AM
- Checked
- Aug 25, 2026, 11:24 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
Read original at benzingaKanzhun shares are trading higher after the company reported better-than-expected Q2 EPS results.
Read original at benzingaTranscript: Kanzhun Q2 2026 Earnings Conference Call
Kanzhun (NASDAQ:BZ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Read original at benzinga